Luxury skincare brand RAS Luxury Skincare and medical supplies platform Zoplar have raised $5 million and $3.4 million, respectively, in their Series A funding rounds.
Unilever leads funding in RAS Luxury Skincare
RAS Luxury Skincare on Wednesday announced that it has raised $5 million in its Series A funding round led by Unilever’s investment arm, Unilever Ventures.
The round also saw participation from Amazon Smbhav Venture Fund and RAS’s existing investors, including Sixth Sense Ventures and other notable angel investors, such as Mr Keki Mistry’s Family.
RAS will leverage the fresh capital to expand its retail footprint, focusing on exclusive brand outlets (EBOs) and shop-in-shop retail, it said in a statement.
Founded in 2017 by Shubhika Jain, Suramya Jain, and Sangeeta Jain, the company currently operates two EBOs, with 50 more pan-India EBOs planned over the next three years. Other areas of investment include talent acquisition, R&D for new product lines, branding and marketing efforts, and technology enhancement to bolster customer experience.
RAS claims to have experienced growth at 140% CAGR over the past year, with its D2C channel contributing more than 50% to the revenue. This is followed by contributions from e-commerce and quick commerce platforms such as Nykaa, Amazon, Flipkart, Tira, Blinkit, Zepto, Myntra and more.
With offline retail expansion being one of the focus areas post-funding, the company is eyeing 25% of revenue contribution from offline channels over the next four years.
Zoplar raises $3.4m led by Blume Ventures
Medical supplies platform Zoplar has secured $3.4 million in a Series A funding round led by Blume Ventures, per an announcement.
Beenext, Saison Capital, Atrium Angels, Finfirst, and LogX also participated in the round.
The fresh capital proceeds will be used by Zoplar to boost its operational capacity by focusing on backward integration in the supply chain and building a service engineering team, the company said in a statement.
Founded by Amit Sah and Umesh Sharma in 2022, Zoplar aims to address the challenges faced by MSME hospitals, such as navigating product pricing complexities, managing multiple vendor relationships, ensuring quality after-sales service, and securing financing options.
Since its launch, Zoplar claims to have forged partnerships with approximately 300 hospitals, including leading nephrology chains like DCDC, achieving a 40% repeat customer rate.
